Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treatment of Neovascular Age-Related Macular Degeneration
Despite the success of anti-vascular endothelial growth factors (anti-VEGFs), currently, there is a need for highly effective compounds that can alleviate the burden of managing neovascular age-related macular degeneration (nAMD). To review the milestones in the molecular and clinical development of...
Uloženo v:
| Vydáno v: | Ophthalmologica (Basel) Ročník 244; číslo 2; s. 93 |
|---|---|
| Hlavní autoři: | , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
Switzerland
01.05.2021
|
| Témata: | |
| ISSN: | 1423-0267, 1423-0267 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Despite the success of anti-vascular endothelial growth factors (anti-VEGFs), currently, there is a need for highly effective compounds that can alleviate the burden of managing neovascular age-related macular degeneration (nAMD).
To review the milestones in the molecular and clinical development of brolucizumab, the first single-chain antibody fragment (scFv) designed specifically for intraocular use in humans.
In this article, we summarize the preclinical and current clinical evidence of brolucizumab administration with an overview of the other treatment regimens and additional indications under investigation.
The unique molecular design of brolucizumab led to a low molecular weight of only 26 kDa, allowing for a concentrated molar dose of 1 intravitreal injection compared with other anti-VEGF agents. Phase I and II clinical trial outcomes validated the efficacy of brolucizumab in the treatment of nAMD with signals of a more durable treatment effect. The pivotal phase III trials, HAWK and HARRIER, which included a total of 1,817 patients, established that brolucizumab can be administered every 3 months while maintaining disease control.
The preclinical and clinical data on brolucizumab provide evidence of sustained disease control with longer injection intervals, thus potentially reducing the treatment burden in patients with nAMD. |
|---|---|
| AbstractList | Despite the success of anti-vascular endothelial growth factors (anti-VEGFs), currently, there is a need for highly effective compounds that can alleviate the burden of managing neovascular age-related macular degeneration (nAMD).BACKGROUNDDespite the success of anti-vascular endothelial growth factors (anti-VEGFs), currently, there is a need for highly effective compounds that can alleviate the burden of managing neovascular age-related macular degeneration (nAMD).To review the milestones in the molecular and clinical development of brolucizumab, the first single-chain antibody fragment (scFv) designed specifically for intraocular use in humans.PURPOSETo review the milestones in the molecular and clinical development of brolucizumab, the first single-chain antibody fragment (scFv) designed specifically for intraocular use in humans.In this article, we summarize the preclinical and current clinical evidence of brolucizumab administration with an overview of the other treatment regimens and additional indications under investigation.METHODSIn this article, we summarize the preclinical and current clinical evidence of brolucizumab administration with an overview of the other treatment regimens and additional indications under investigation.The unique molecular design of brolucizumab led to a low molecular weight of only 26 kDa, allowing for a concentrated molar dose of 1 intravitreal injection compared with other anti-VEGF agents. Phase I and II clinical trial outcomes validated the efficacy of brolucizumab in the treatment of nAMD with signals of a more durable treatment effect. The pivotal phase III trials, HAWK and HARRIER, which included a total of 1,817 patients, established that brolucizumab can be administered every 3 months while maintaining disease control.RESULTSThe unique molecular design of brolucizumab led to a low molecular weight of only 26 kDa, allowing for a concentrated molar dose of 1 intravitreal injection compared with other anti-VEGF agents. Phase I and II clinical trial outcomes validated the efficacy of brolucizumab in the treatment of nAMD with signals of a more durable treatment effect. The pivotal phase III trials, HAWK and HARRIER, which included a total of 1,817 patients, established that brolucizumab can be administered every 3 months while maintaining disease control.The preclinical and clinical data on brolucizumab provide evidence of sustained disease control with longer injection intervals, thus potentially reducing the treatment burden in patients with nAMD.CONCLUSIONSThe preclinical and clinical data on brolucizumab provide evidence of sustained disease control with longer injection intervals, thus potentially reducing the treatment burden in patients with nAMD. Despite the success of anti-vascular endothelial growth factors (anti-VEGFs), currently, there is a need for highly effective compounds that can alleviate the burden of managing neovascular age-related macular degeneration (nAMD). To review the milestones in the molecular and clinical development of brolucizumab, the first single-chain antibody fragment (scFv) designed specifically for intraocular use in humans. In this article, we summarize the preclinical and current clinical evidence of brolucizumab administration with an overview of the other treatment regimens and additional indications under investigation. The unique molecular design of brolucizumab led to a low molecular weight of only 26 kDa, allowing for a concentrated molar dose of 1 intravitreal injection compared with other anti-VEGF agents. Phase I and II clinical trial outcomes validated the efficacy of brolucizumab in the treatment of nAMD with signals of a more durable treatment effect. The pivotal phase III trials, HAWK and HARRIER, which included a total of 1,817 patients, established that brolucizumab can be administered every 3 months while maintaining disease control. The preclinical and clinical data on brolucizumab provide evidence of sustained disease control with longer injection intervals, thus potentially reducing the treatment burden in patients with nAMD. |
| Author | Weissgerber, Georges Holz, Frank G Tadayoni, Ramin Clemens, Andreas Verma, Rohini Sararols, Laura |
| Author_xml | – sequence: 1 givenname: Ramin surname: Tadayoni fullname: Tadayoni, Ramin organization: Université de Paris, Ophthalmology Department, AP-HP, Hôpital Lariboisière, Paris, France – sequence: 2 givenname: Laura surname: Sararols fullname: Sararols, Laura organization: Hospital General de Catalunya, Barcelona, Spain – sequence: 3 givenname: Georges surname: Weissgerber fullname: Weissgerber, Georges organization: Novartis Pharma AG, Basel, Switzerland – sequence: 4 givenname: Rohini surname: Verma fullname: Verma, Rohini organization: Novartis Pharma AG, Basel, Switzerland – sequence: 5 givenname: Andreas surname: Clemens fullname: Clemens, Andreas email: andreas.clemens@novartis.com, andreas.clemens@novartis.com organization: Department of Cardiology and Angiology I, Heart Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany, andreas.clemens@novartis.com – sequence: 6 givenname: Frank G surname: Holz fullname: Holz, Frank G organization: Department of Ophthalmology, University of Bonn, Bonn, Germany |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/33197916$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkEtPwzAQhC1URB9w4A8gH7kE7Nh5mFvoC6QWJFS4Ro6zKUFOXBynqPx6LFEkTrua_Wak2TEatKYFhC4puaE0EreEkIgywtMTNKI8ZAEJ42Twbx-icdd9EOJhQc_QkDEqEkHjEXL31uhe1d99I4s7nOEn-NIHPIM9aLODEmetq4O3-XKB10aD6jXgyljs3gFvLEjXQOuwqbzP7GXn79LibAvBC2jpvH8tf7UZbKEFK11t2nN0WkndwcVxTtDrYr6ZPgSr5-XjNFsFirPIBZJIKBmpZMiriCS0LNOCRzxWkRcJB-F1xnxvkSZVlbA0UQWUqigiCFUpZThB17-5O2s-e-hc3tSdAq1lC6bv8pDHlPkUwTx6dUT7ooEy39m6kfaQ_30q_AGmTGuq |
| CitedBy_id | crossref_primary_10_3390_ijerph18168450 crossref_primary_10_1016_j_ijbiomac_2025_144151 crossref_primary_10_1126_scitranslmed_abq5241 crossref_primary_10_3390_cancers16020350 crossref_primary_10_7759_cureus_52176 crossref_primary_10_3390_biomedicines10051003 crossref_primary_10_1172_JCI144469 crossref_primary_10_1159_000530544 crossref_primary_10_1016_j_oret_2024_07_012 crossref_primary_10_1016_j_pep_2024_106499 crossref_primary_10_1097_MD_0000000000027580 crossref_primary_10_1016_j_addr_2023_114864 crossref_primary_10_1016_j_bcp_2024_116303 crossref_primary_10_1007_s40123_025_01141_y crossref_primary_10_1371_journal_pone_0317678 crossref_primary_10_1016_j_ajo_2025_03_016 crossref_primary_10_1007_s00417_022_05591_z crossref_primary_10_1016_j_yaoo_2023_02_010 crossref_primary_10_3389_fcell_2024_1368021 crossref_primary_10_1016_j_survophthal_2024_09_011 crossref_primary_10_3390_pharmaceutics15010205 crossref_primary_10_1055_a_2642_2305 crossref_primary_10_3390_pharmaceutics17030394 crossref_primary_10_36469_jheor_2025_129832 crossref_primary_10_1002_jbm_a_37626 crossref_primary_10_1111_jdi_14195 crossref_primary_10_1155_2024_3673930 crossref_primary_10_3390_life14020246 crossref_primary_10_4103_pajo_pajo_116_24 crossref_primary_10_1063_5_0158032 crossref_primary_10_3928_23258160_20230221_04 crossref_primary_10_2147_OPTH_S339393 crossref_primary_10_3390_cells11213453 crossref_primary_10_3389_fendo_2024_1347864 crossref_primary_10_1007_s12325_022_02193_3 crossref_primary_10_3390_ph16040562 crossref_primary_10_1007_s10384_022_00922_3 crossref_primary_10_1016_j_ajoc_2022_101521 crossref_primary_10_1177_24741264251332515 crossref_primary_10_1111_aos_15242 crossref_primary_10_1136_bmjopen_2025_099551 crossref_primary_10_1080_02713683_2024_2441245 crossref_primary_10_1186_s40942_024_00566_0 crossref_primary_10_1177_11206721231187663 crossref_primary_10_3390_medicina60071170 crossref_primary_10_3390_diagnostics13050975 crossref_primary_10_1080_08820538_2023_2271095 crossref_primary_10_1007_s10792_023_02870_4 crossref_primary_10_2147_DDDT_S378450 crossref_primary_10_1080_14740338_2024_2387318 crossref_primary_10_1007_s00417_023_06241_8 crossref_primary_10_1007_s10456_024_09960_6 crossref_primary_10_1007_s11095_024_03773_4 crossref_primary_10_1158_2326_6066_CIR_24_0876 crossref_primary_10_3389_fphar_2022_890732 crossref_primary_10_1007_s00417_024_06374_4 crossref_primary_10_1016_j_cmpb_2023_107364 crossref_primary_10_22270_jddt_v15i7_7283 crossref_primary_10_3389_fimmu_2023_1107295 crossref_primary_10_3341_kjo_2023_0009 crossref_primary_10_1016_j_ajo_2025_08_018 crossref_primary_10_1007_s40266_023_01068_8 crossref_primary_10_1080_07853890_2022_2064541 crossref_primary_10_2147_OPTH_S425709 crossref_primary_10_1016_j_omtm_2023_101145 crossref_primary_10_1159_000526851 crossref_primary_10_21561_jor_2025_10_1_20 crossref_primary_10_1177_11206721241310262 crossref_primary_10_3389_fphar_2023_1307860 crossref_primary_10_1016_j_ajoc_2021_101197 crossref_primary_10_1016_j_ophtha_2024_06_011 crossref_primary_10_3390_pharmaceutics15051416 crossref_primary_10_3390_jcm14145141 crossref_primary_10_1097_APO_0000000000000602 crossref_primary_10_1080_14656566_2022_2154145 crossref_primary_10_1038_s41598_023_38173_y crossref_primary_10_3390_medicina58091180 crossref_primary_10_1016_j_adaj_2021_12_008 crossref_primary_10_3389_fmicb_2022_899578 crossref_primary_10_3390_ijms24119591 crossref_primary_10_3390_ijms241613004 crossref_primary_10_1136_bjo_2023_323577 crossref_primary_10_3390_life14101220 crossref_primary_10_1177_11206721241286708 crossref_primary_10_1159_000527815 crossref_primary_10_36469_001c_129832 crossref_primary_10_3390_medicina58121870 crossref_primary_10_1097_IAE_0000000000003769 crossref_primary_10_1007_s00417_023_06038_9 crossref_primary_10_3390_pharmaceutics14020265 crossref_primary_10_3341_kjo_2023_0133 crossref_primary_10_1038_s41598_024_51315_0 crossref_primary_10_1038_s41433_023_02439_6 crossref_primary_10_3390_pharmaceutics13071102 crossref_primary_10_1177_11206721231207459 crossref_primary_10_3390_ijms23169424 |
| ContentType | Journal Article |
| Copyright | 2021 S. Karger AG, Basel. |
| Copyright_xml | – notice: 2021 S. Karger AG, Basel. |
| DBID | NPM 7X8 |
| DOI | 10.1159/000513048 |
| DatabaseName | PubMed MEDLINE - Academic |
| DatabaseTitle | PubMed MEDLINE - Academic |
| DatabaseTitleList | MEDLINE - Academic PubMed |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1423-0267 |
| ExternalDocumentID | 33197916 |
| Genre | Journal Article Review |
| GroupedDBID | --- .55 .GJ 0R~ 0~5 0~B 123 29N 30W 329 34G 39C 3O- 3O. 4.4 53G 5RE 7X7 88E 8AO 8FI 8FJ 8FW 8G5 8UI AALGM AAYIC ABBTS ABDBF ABJNI ABOCM ABPAZ ABUWG ABWCG ACGFS ACNCT ACPSR ACQXL ACUHS ADAGL ADBBV AENEX AEYAO AFFNX AFJJK AFKRA AFSIO AHFRZ AHMBA ALDHI ALIPV ALMA_UNASSIGNED_HOLDINGS AZPMC AZQEC BENPR BPHCQ BVXVI CAG CCPQU COF CS3 CYUIP DU5 DWQXO E0A EBS EJD FB. FYUFA GNUQQ GUQSH HMCUK HZ~ IY7 KUZGX L7B M1P M2O N9A NPM O1H O9- PHGZM PHGZT PJZUB PPXIY PQQKQ PROAC PSQYO RIG RKO RXVBD UJ6 UKHRP X7M ZGI ZXP 7X8 |
| ID | FETCH-LOGICAL-c435t-a0aed30fa24f5071dd8b4546c530f04e924f33304987ff7387cbedcbb5e2cdaa2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 105 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000647629000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1423-0267 |
| IngestDate | Thu Sep 04 17:29:05 EDT 2025 Mon Jul 21 05:55:58 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 2 |
| Keywords | Neovascular age-related macular degeneration (AMD) Anti-VEGF Brolucizumab Single-chain antibody fragment |
| Language | English |
| License | 2021 S. Karger AG, Basel. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c435t-a0aed30fa24f5071dd8b4546c530f04e924f33304987ff7387cbedcbb5e2cdaa2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://www.karger.com/Article/Pdf/513048 |
| PMID | 33197916 |
| PQID | 2461392493 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2461392493 pubmed_primary_33197916 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-05-01 |
| PublicationDateYYYYMMDD | 2021-05-01 |
| PublicationDate_xml | – month: 05 year: 2021 text: 2021-05-01 day: 01 |
| PublicationDecade | 2020 |
| PublicationPlace | Switzerland |
| PublicationPlace_xml | – name: Switzerland |
| PublicationTitle | Ophthalmologica (Basel) |
| PublicationTitleAlternate | Ophthalmologica |
| PublicationYear | 2021 |
| SSID | ssj0015991 |
| Score | 2.560886 |
| SecondaryResourceType | review_article |
| Snippet | Despite the success of anti-vascular endothelial growth factors (anti-VEGFs), currently, there is a need for highly effective compounds that can alleviate the... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 93 |
| Title | Brolucizumab: A Newly Developed Anti-VEGF Molecule for the Treatment of Neovascular Age-Related Macular Degeneration |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/33197916 https://www.proquest.com/docview/2461392493 |
| Volume | 244 |
| WOSCitedRecordID | wos000647629000001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV07T8MwELaAIsTC-1FeMhKrRRondcKCImhhIFWHgrpFTnyuKpWk0BQJfj1nJ6UTEhJLhossJfb58p3vy32EXKWp6UsUcMZVyBniW8mkNBsPZKBbWoehsj8KP4leLxgOw3594DaraZWLmGgDtSoyc0Z-bfqecZMs8NvpGzOqUaa6WktorJIGx7vGq8VwWUXwQ6uY10LIwIzSUt1ZCO1Wyw7Dtxf8jiztF6a7_d9n2yFbNbakUeUMu2QF8j2yEdfV831SYs49mWfjr_mrTG9oRDHCTT5pzRsCRaO8HLOXzkOXxpVqLlDEtBQxIh0sCOm00Djuh8FKoxEwy6jD8bGsbPcwst2szaIfkOduZ3D3yGrVBZYhdCqZdCQo7mjpetqARaWC1PO9duaj0fEA31NzcwoSBkJrwQORpaCyNPXBzZSU7iFZy4scjgnVoVSyJV0nUOCJNq6-grYLQoSpwswNmuRyMZ8JerUpVcgcivksWc5okxxVi5JMq_YbCceoIRDVnvxh9CnZdA0JxTIUz0hD456Gc7KefZTj2fuFdRe89vrxNySQy54 |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Brolucizumab%3A+A+Newly+Developed+Anti-VEGF+Molecule+for+the+Treatment+of+Neovascular+Age-Related+Macular+Degeneration&rft.jtitle=Ophthalmologica+%28Basel%29&rft.au=Tadayoni%2C+Ramin&rft.au=Sararols%2C+Laura&rft.au=Weissgerber%2C+Georges&rft.au=Verma%2C+Rohini&rft.date=2021-05-01&rft.issn=1423-0267&rft.eissn=1423-0267&rft.volume=244&rft.issue=2&rft.spage=93&rft_id=info:doi/10.1159%2F000513048&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1423-0267&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1423-0267&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1423-0267&client=summon |